Small interfering RNA targeting TPX2 can effectively reduce the growth of pancreatic cancer cells in vitro and induce apoptosis.[69] TPX2 also shows potential as a novel intervention target and biomarker for COVID-19.[47] As an antigenic component of a polyvalent recombinant fusion protein prophylactic vaccine, TPX2 promotes the production of high-titer antigen-specific antibodies and their isotypes. Here, TPX2 is linked to pancreatic neoplasm.